GLUE
Monte Rosa Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-36/100
Last price
10.01
▼ 0.26 (2.53%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
10.27
Prev close
10.27
Day high
10.38
Day low
9.78
Volume
1.05M
Market cap
$842.04M
P/E (TTM)
—
52W range
7.44 – 25.77
Day trading desk
Gap from prior close
-0.00%
Prior close 10.27
VWAP
9.91
+0.96% from price
Relative volume
1.38×
Normal
Session range
20.08%
9.66 – 11.60
Position in range
18%
Near session low
ATR (14D)
0.63
6.25% of price
Prior day high
10.59
PDH
Prior day low
10.04
PDL
Bid / ask spread
—
Quote not published
Session volume
1.81M
Avg 1.31M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-15.93%
-17.9%
1M
-28.68%
-29.8%
3M
-58.98%
-63.5%
6M
-42.35%
-60.5%
YTD
-37.05%
-51.3%
1Y
+27.52%
+11.1%
3Y
+106.05%
+23.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on GLUE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-40.12K
Net selling
Buy transactions
14
98.46K shares
Sell transactions
19
138.58K shares
Net transactions
+33
Buys less sells
Sell : buy shares
1.4 : 1
Mixed
Insider-held shares
478.61K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 16, 26 | WARMUTH MARKUS M.D. Chief Executive Officer |
SELL | 9.50K | $220.22K | Direct |
| Jul 15, 26 | CHAMPOUX JENNIFER Chief Operating Officer |
SELL | 4.35K | $101.73K | Direct |
| Jul 15, 26 | CHAMPOUX JENNIFER Chief Operating Officer |
CONVERSION | 4.35K | $17.32K | Direct |
| Jul 6, 26 | TOWNSON SHARON Officer |
SELL | 6.00K | $139.85K | Direct |
| Jul 6, 26 | TOWNSON SHARON Officer |
CONVERSION | 6.00K | $36.84K | Direct |
| Jun 30, 26 | JANKU FILIP Officer |
SELL | 5.41K | $132.47K | Direct |
| Jun 30, 26 | JANKU FILIP Officer |
CONVERSION | 5.41K | $72.51K | Direct |
| Jun 29, 26 | MANNING ANTHONY M Director |
SELL | 10.00K | $231.10K | Direct |
| Jun 29, 26 | MANNING ANTHONY M Director |
CONVERSION | 10.00K | $41.60K | Direct |
| Jun 29, 26 | JANKU FILIP Officer |
SELL | 6.00K | $137.70K | Direct |
| Jun 29, 26 | JANKU FILIP Officer |
CONVERSION | 6.00K | $45.36K | Direct |
| Jun 24, 26 | JANKU FILIP Officer |
SELL | 41.84K | $882.20K | Direct |
| Jun 24, 26 | JANKU FILIP Officer |
CONVERSION | 36.00K | $272.16K | Direct |
| Jun 23, 26 | TOWNSON SHARON Officer |
SELL | 3.00K | $60.00K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BOWEN MATTHEW |
Officer | 25.90K | Stock Award(Grant) |
CHAMPOUX JENNIFER |
Chief Operating Officer | 62.37K | Sale |
DUNN EDMUND |
Officer | 22.55K | Sale |
JANKU FILIP |
Officer | 60.61K | Sale |
LEO CHANDRA P. MD |
Director | 10.00K | Purchase |
MANNING ANTHONY M |
Director | 0 | Sale |
NICKSON PHILIP |
Officer | 55.00K | Sale |
TOWNSON SHARON |
Officer | 67.84K | Sale |
VERSANT VENTURE CAPITAL VI, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
WARMUTH MARKUS M.D. |
Chief Executive Officer | 585.04K | Sale |
Fundamentals
Market cap$842.04M
Enterprise value$258.93M
Revenue (TTM)$28.73M
Gross profit$-133.63M
EBITDA$-173.73M
Net income$-161.12M
EPS (TTM)$-1.75
Free cash flow$-74.45M
Total cash$621.10M
Total debt$37.99M
Book value / share$5.72
Shares outstanding85.31M
Float54.48M
Short % of float22.94%
Dividend yield0.00%
Beta (5Y)1.37
Valuation & profitability ratios
Trailing P/E—
Forward P/E-5.07
PEG ratio—
Price / sales—
Price / book1.73
EV / revenue9.01
EV / EBITDA-1.49
Gross margin0.00%
Operating margin-547.84%
Profit margin0.00%
Return on equity-42.66%
Return on assets-21.63%
Debt / equity7.80
Current ratio10.58
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $123.67M | $75.62M | $0 | $0 | +63.5% |
| Operating revenue | $123.67M | $75.62M | $0 | $0 | +63.5% |
| Research & development | $141.50M | $121.56M | $111.27M | $85.06M | +16.4% |
| Selling, general & admin | $36.38M | $35.17M | $32.04M | $27.32M | +3.4% |
| Total operating expense | $177.88M | $156.73M | $143.31M | $112.38M | +13.5% |
| Operating income | -$54.21M | -$81.11M | -$143.31M | -$112.38M | +33.2% |
| Net interest income | $12.94M | $10.57M | $9.33M | $3.76M | +22.5% |
| Pre-tax income | -$39.72M | -$70.13M | -$135.01M | -$108.50M | +43.4% |
| Tax provision | -$1.10M | $2.57M | $338.00K | $0 | -142.7% |
| Net income | -$38.63M | -$72.70M | -$135.35M | -$108.50M | +46.9% |
| Net income to common | -$38.63M | -$72.70M | -$135.35M | -$108.50M | +46.9% |
| Basic EPS | -0.59 | -1.18 | -2.63 | -2.30 | +50.1% |
| Diluted EPS | -0.59 | -1.18 | -2.63 | -2.30 | +50.1% |
| EBIT | -$54.21M | -$81.11M | -$143.31M | -$112.38M | +33.2% |
| EBITDA | -$45.85M | -$72.99M | -$137.09M | -$108.64M | +37.2% |
| Basic shares | 65.54M | 61.51M | 51.40M | 47.23M | +6.6% |
| Diluted shares | 65.54M | 61.51M | 51.40M | 47.23M | +6.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $129.88M | $224.25M | $128.10M | $54.91M | -42.1% |
| Cash & short-term investments | $377.10M | $372.15M | $232.41M | $262.83M | +1.3% |
| Total current assets | $393.19M | $377.44M | $236.21M | $275.89M | +4.2% |
| Property, plant & equipment | $50.37M | $56.31M | $62.61M | $61.91M | -10.6% |
| Total assets | $448.66M | $438.73M | $303.75M | $342.39M | +2.3% |
| Total current liabilities | $64.21M | $156.95M | $46.59M | $25.57M | -59.1% |
| Total debt | $39.19M | $42.72M | $46.04M | $47.00M | -8.3% |
| Total liabilities | $215.60M | $215.80M | $124.50M | $70.98M | -0.1% |
| Retained earnings | -$477.21M | -$438.59M | -$365.89M | -$230.54M | -8.8% |
| Shareholder equity | $233.06M | $222.94M | $179.25M | $271.41M | +4.5% |
| Working capital | $328.97M | $220.49M | $189.62M | $250.32M | +49.2% |
| Net tangible assets | $233.06M | $222.94M | $179.25M | $271.41M | +4.5% |
| Shares issued | 65.54M | 61.51M | 50.14M | 49.45M | +6.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$38.63M | -$72.70M | -$135.35M | -$108.50M | +46.9% |
| Depreciation & amortisation | $8.36M | $8.12M | $6.22M | $3.75M | +2.9% |
| Stock-based compensation | $18.86M | $18.13M | $16.67M | $11.66M | +4.1% |
| Change in working capital | -$9.19M | $91.40M | $72.47M | -$2.13M | -110.1% |
| Operating cash flow | -$22.80M | $42.00M | -$43.80M | -$92.47M | -154.3% |
| Capital expenditure | -$4.70M | -$3.99M | -$19.04M | -$12.91M | -17.9% |
| Investing cash flow | -$101.83M | -$44.45M | $88.80M | -$219.22M | -129.1% |
| Share buybacks | -$357.00K | -$641.00K | -$116.00K | — | +44.3% |
| Financing cash flow | $30.35M | $98.89M | $27.49M | $20.47M | -69.3% |
| Free cash flow | -$27.50M | $38.01M | -$62.84M | -$105.38M | -172.3% |
| End cash position | $134.84M | $229.12M | $132.68M | $60.19M | -41.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $8.97M | $4.21M | $2.78M | $12.77M | $23.19M | +113.0% |
| Operating revenue | $8.97M | $4.21M | $2.78M | $12.77M | $23.19M | +113.0% |
| Research & development | $47.96M | $44.07M | $41.98M | $36.68M | $30.65M | +8.8% |
| Selling, general & admin | $10.13M | $10.18M | $10.52M | $9.06M | $8.10M | -0.4% |
| Total operating expense | $58.10M | $54.24M | $52.50M | $45.74M | $38.75M | +7.1% |
| Operating income | -$49.13M | -$50.03M | -$49.72M | -$32.98M | -$15.55M | +1.8% |
| Net interest income | $5.92M | $5.59M | $3.69M | $2.75M | $3.07M | +5.8% |
| Pre-tax income | -$43.19M | -$44.45M | -$46.08M | -$30.26M | -$11.10M | +2.8% |
| Tax provision | $208.00K | $52.00K | $59.00K | -$3.18M | $1.20M | +300.0% |
| Net income | -$43.40M | -$44.50M | -$46.13M | -$27.08M | -$12.29M | +2.5% |
| Net income to common | -$43.40M | -$44.50M | -$46.13M | -$27.08M | -$12.29M | +2.5% |
| Basic EPS | -0.51 | -0.53 | -0.70 | -0.44 | -0.20 | +3.5% |
| Diluted EPS | -0.51 | -0.53 | -0.70 | -0.44 | -0.20 | +3.5% |
| EBIT | -$49.13M | -$50.03M | -$49.72M | -$32.98M | -$15.55M | +1.8% |
| EBITDA | -$47.22M | -$48.01M | -$47.63M | -$30.88M | -$13.43M | +1.6% |
| Basic shares | 85.23M | 84.32M | 65.54M | 61.79M | 61.72M | +1.1% |
| Diluted shares | 85.23M | 84.32M | 65.54M | 61.79M | 61.72M | +1.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $90.10M | $159.86M | $129.88M | $208.34M | $69.43M | -43.6% |
| Cash & short-term investments | $621.10M | $666.22M | $377.10M | $391.26M | $290.59M | -6.8% |
| Total current assets | $631.41M | $677.55M | $393.19M | $401.82M | $299.46M | -6.8% |
| Property, plant & equipment | $53.99M | $53.10M | $50.37M | $52.66M | $54.73M | +1.7% |
| Total assets | $691.16M | $736.43M | $448.66M | $459.84M | $359.59M | -6.1% |
| Total current liabilities | $59.66M | $71.04M | $64.21M | $61.44M | $41.85M | -16.0% |
| Total debt | $37.99M | $39.06M | $39.19M | $40.17M | $41.13M | -2.8% |
| Total liabilities | $203.88M | $214.51M | $215.60M | $214.00M | $91.51M | -5.0% |
| Retained earnings | -$565.11M | -$521.72M | -$477.21M | -$431.08M | -$404.00M | -8.3% |
| Shareholder equity | $487.28M | $521.92M | $233.06M | $245.84M | $268.08M | -6.6% |
| Working capital | $571.75M | $606.51M | $328.97M | $340.37M | $257.61M | -5.7% |
| Net tangible assets | $487.28M | $521.92M | $233.06M | $245.84M | $268.08M | -6.6% |
| Shares issued | 85.23M | 84.32M | 65.54M | 61.79M | 61.72M | +1.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$43.40M | -$44.50M | -$46.13M | -$27.08M | -$12.29M | +2.5% |
| Depreciation & amortisation | $1.91M | $2.03M | $2.09M | $2.10M | $2.13M | -5.7% |
| Stock-based compensation | $5.97M | $5.95M | $4.31M | $4.36M | $4.89M | +0.4% |
| Change in working capital | -$7.63M | $141.00K | -$3.36M | $121.52M | -$28.71M | -5,508.5% |
| Operating cash flow | -$44.11M | -$37.37M | -$43.01M | $100.43M | -$34.72M | -18.0% |
| Capital expenditure | -$4.72M | -$1.87M | -$767.00K | -$651.00K | -$1.70M | -152.8% |
| Investing cash flow | -$28.86M | -$261.00M | -$65.07M | $38.14M | $25.32M | +88.9% |
| Share buybacks | — | — | -$357.00K | — | — | — |
| Financing cash flow | $3.21M | $328.33M | $29.62M | $348.00K | $365.00K | -99.0% |
| Free cash flow | -$48.84M | -$39.24M | -$43.78M | $99.78M | -$36.41M | -24.5% |
| End cash position | $95.04M | $164.81M | $134.84M | $213.29M | $74.38M | -42.3% |
Options analytics
Put / call volume
7.87
Put-heavy session
Put / call open interest
11.50
Positioning, not flow
Max pain
25.00
+153.3% from spot
ATM implied vol
3.1%
Nearest strike to spot
Skew (10% OTM)
-3.1%
Calls bid over puts
Call volume
23
Contracts, this expiry
Put volume
181
Contracts, this expiry
Heaviest call OI
2.50
2 contracts
Heaviest put OI
25.00
16 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.37 | -0.43 | -17.6% |
| Mar 2026 | -0.38 | -0.45 | -19.1% |
| Dec 2025 | -0.34 | -0.55 | -63.4% |
| Sep 2025 | -0.35 | -0.33 | +6.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.22 | 8 | $31.50M | +146.7% |
| Next quarter | -0.35 | 8 | $23.18M | +733.5% |
| Current year | -1.43 | 8 | $67.43M | -45.5% |
| Next year | -1.95 | 8 | $53.93M | -20.0% |
Analyst targets & ownership
Mean target$28.00
High target$37.00
Low target$25.00
Implied upside179.72%
Analyst count7
ConsensusSTRONG BUY
Strong buy / Buy2 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders0.56%
Held by institutions116.12%
Institutions holding265
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
11.27
-11.15% from price
SMA 20
12.22
-19.24% from price
SMA 50
14.31
-31.02% from price
SMA 100
17.44
-42.60% from price
SMA 200
18.12
-45.52% from price
EMA 12
11.36
-11.90% from price
EMA 26
12.55
-20.22% from price
EMA 50
14.23
-29.68% from price
RSI (14)
20.8
Oversold
MACD (12,26,9)
-1.18
Hist -0.09
ATR (14)
0.63
6.34% of price
Realised vol 30D
51.3%
Annualised
Bollinger upper
14.68
20, 2σ
Bollinger lower
9.76
20, 2σ
50 / 200 cross
Death
14.31 vs 18.12
Trend bias
Below 200
-45.52%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.73
Less volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
51.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-61.0%
Peak to trough
Max drawdown 5Y
-90.8%
Peak to trough
ATR 14
0.63
6.34% of price
Beta (reported)
1.37
5Y monthly, from filing
Short interest
Shares short
19.27M
Prior 17.46M
Change vs prior
+10.4%
Shorts adding
% of float
22.94%
Heavily shorted
% of shares out
22.58%
Against total outstanding
Days to cover
17.1
Crowded exit
Float
54.48M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 1, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
| Sep 9, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 25, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 7, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Aug 7, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 7, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Aug 3, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jun 30, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| May 11, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Mar 18, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Mar 18, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-01
Corporate Changes & Voting Matters
8-K · 2026-09-08
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-11
Periodic Financial Reports
10-Q · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-29
Periodic Financial Reports
10-K · 2026-03-17
Offering Registrations
S-3ASR · 2026-02-11
Headlines
Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study
MarketBeat · 22h ago
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 4d ago
Sector Update: Healthcare Stocks Decline Premarket Thursday
MT Newswires · 6d ago
Sector Update: Healthcare
MT Newswires · 6d ago
Monte Rosa Therapeutics Says MRT-8102 Showed Biomarker Improvements in Phase 1 Study
MT Newswires · 6d ago
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
GlobeNewswire · 6d ago
HC Wainwright Initiates Monte Rosa Therapeutics at Buy With $25 Price Target
MT Newswires · 6d ago
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
GlobeNewswire · 6d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.